Skip to main content

Table 3 Change in serum biomarkers and liver stiffness over time during antiviral therapy*

From: Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-centre study

 

Baseline

24.week

48.week

LSM, 2D-SWE (kPa)

9.24 (5.8–19.9)

8.01 (6.1–17.5)a

7.36 (5.4–15.0)a,b

LSM, 2D-SWE (m/s)

1.79 (1.34–2.65)

1.57 (1.34–2.43)a

1.44 (1.33–2.21)a,b

APRI

0.39 (0.12–1.93)

0.32 (0.11–1.44)a

0.30 (0.06–1.15)a

FIB-4

0.83 (0.17–3.22)

0.79 (0.16–3.64)a

0.75 (0.16–3.96)a

ALT (U/L)

45.1 (5–195)

32.1 (8–168)a

30.5 (7–144)a

AST (U/L)

30.9 (13–157)

25.7 (12–98)a

25.6 (6–72)a

INR

1.12 (0.96–1.38)

1.13 (0.97–1.77)

1.13 (0.99–1.36)

PLT (109/L)

201 (69–364)

212 (74–427)

223 (94–373)

HBV DNA (IU/ml)

95,816,415

127732a

794a,b

  1. LSM Liver stiffness measurement, 2D-SWE Two dimensional share wave elastography, APRI AST-to platelet ratio index, FIB-4 F ibrosis 4, ALT Alanine aminotransferase, AST Aspartate aminotransferase, INR International normalized ratio, PLT Platelet
  2. ap < 0.005 compared to baseline
  3. bp < 0.005 compared to week 24
  4. *It included 84 patients under antiviral therapy